Simple Summary This review article presents a synopsis of the key clinical developments,
their limitations, and future perspectives in the treatment of pancreatic cancer. In the first part …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in
the US, and it is expected to be the second leading cause of cancer deaths by 2030. The …

Background Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX are standard first-line
treatment options for advanced pancreatic ductal adenocarcinoma (aPDAC), but currently …

Purpose: Characterizing germline and somatic ATM variants (g ATM m, s ATM m) zygosity
and their contribution to homologous recombination deficiency (HRD) is important for …

Abstract Background FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GnP) have
been recommended as the first-line chemotherapy for metastatic pancreatic cancer (mPC) …

The most effective treatment of pancreatic cancer (PC) is known as mFOLFIRINOX scheme.
However, this regimen has relatively severe toxic effects and are commonly restricted to …

Abstract Treatment outcomes between FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan,
and oxaliplatin) and GNP (gemcitabine with albumin-bound paclitaxel) as first-line …

Pancreatic cancer has an extremely low prognosis, which is attributable to its high
aggressiveness, invasiveness, late diagnosis, and lack of effective therapies. Among all the …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is a tough cancer. Instead of
stopping certain genes, we used their power to change tumors. Surprisingly, some proteins …

Pancreatic cancer (PC) is among the most devastating digestive tract cancers worldwide.
This cancer is characterized by poor diagnostic detection, lack of therapy, and difficulty in …